Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently reported the remarkable capacity of miR-4510 to impede the growth of HCC and hepatoblastoma through Glypican-3 (GPC3) targeting and Wnt pathway inactivation.
|
31612616 |
2020 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of function mutations in <i>GPC3</i> lead to Simpson-Golabi-Behmel Syndrome, an X-linked overgrowth condition with a predisposition to GPC3-expressing cancers including hepatoblastoma and Wilms tumor.
|
30873384 |
2019 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/β-catenin works in association with other signaling pathways to induce the development of hepatoblastoma including Yes-associated protein (YAP)1 (YAP-1), mammalian target of rapamycin (mTOR) 1 (mTOR-1), SLC38A1, glypican 3 (GPC3), nuclear factor κ-light-chain-enhancer of activated B cells (NF-kB), epidermal growth factor receptor, ERK1/2, tumor necrosis factor-α (TNF-α), regenerating islet-derived 1 and 3 α (REG1A and 3A), substance P (SP)/neurokinin-1 receptor and PARP-1.
|
31511432 |
2019 |
Hepatoblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Contrarily, GPC3 is specifically expressed in hepatocellular carcinoma (HCC), ovarian clear cell carcinoma, melanoma, squamous cell carcinoma of the lung, hepatoblastoma, nephroblastoma (Wilms tumor), yolk sac tumor, and some pediatric cancers.
|
31024850 |
2019 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer.
|
28476031 |
2017 |
Hepatoblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the GPC3 levels in HB pretreatment group were significantly higher than those in NC group and HB remission group but not statistically different from those in BHD group and HB during treatment group.
|
28378832 |
2017 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We observed disease-control rates [complete response (CR)+partial response+stable disease] of 66.7% after 2 months, and although patients in the progression group unable to induce GPC3-peptide-specific cytotoxic T lymphocytes (CTLs) received poor prognoses, patients in the partial-remission and remission groups or those with hepatoblastoma received good prognoses.
|
29296538 |
2017 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beta-catenin, glypican 3 and spalt-like transcription factor 4 immunostaining showed that all the tumours had a mixed HB/HCC immunophenotype.
|
28660626 |
2017 |
Hepatoblastoma
|
0.400 |
Therapeutic
|
disease |
RGD |
Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
|
25449037 |
2015 |
Hepatoblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The current observation of a somatic CTNNB1 mutation in a hepatoblastoma from a patient with a germline GPC3 mutation supports the notion that the mutation in GPC3 may influence one of the initial steps in tumorigenesis and the progression to hepatoblastoma.
|
24459012 |
2014 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We interpret these nodules as neoplastic with most being adenomas (GPC3 negative) that show features of independent origin and represent early stages of carcinogenesis, implying potential to progress to HB or hepatocellular carcinoma.
|
23715166 |
2013 |
Hepatoblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The absence of a functional GPC3 may alter the normal differentiation of embryonal mesodermal tissues predisposing to the development of embryonal tumors, as the index case studied who developed a hepatoblastoma at age 9 months.
|
23463737 |
2013 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
All 65 hepatoblastomas had cytoplasmic immunoreactivity for GPC3 with greater than 90% of cases showing strong, diffuse positivity.
|
17949790 |
2008 |
Hepatoblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of GPC3 in Wilms tumor and hepatoblastoma suggests a growth-promoting or neutral activity for this gene product rather than a growth-suppressive effect.
|
11878776 |
2001 |
Hepatoblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data also suggest that nephroblastomatosis and hepatoblastoma are included in the phenotypic spectrum of GPC3 deletions and SGBS, underscoring the importance of tumor surveillance in these children.
|
11477610 |
2001 |
Hepatoblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MXR7 mRNA was detected in one of two hepatoblastomas but not in hepatocellular adenoma, cholangiocarcinoma, or metastatic carcinomas to the liver.
|
9371521 |
1997 |
Hepatoblastoma
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|